Lv5
950 积分 2021-04-16 加入
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases
6小时前
求助中
ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO
6小时前
求助中
ABS1055 GB261 (CND261), A NOVEL CD20/CD3 T-CELL ENGAGER, HAS A DIFFERENTIATED SAFETY PROFILE AND POTENTIAL FOR DEVELOPMENT IN AUTOIMMUNE DISEASES
2个月前
已关闭
POS0813 CAR T-CELL THERAPY IN SLE: A SYSTEMATIC/SCOPING REVIEW
2个月前
已关闭
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
11个月前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
1年前
已完结
Venture capital contracts
1年前
已完结
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
1年前
已完结
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
1年前
已完结
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
1年前
已完结
皖公网安备34019202002308
